GPX3 methylation is associated with hematologic improvement in low-risk myelodysplastic syndrome patients treated with Pai-Neng-Da

Shujun Yang¹,* , Tong Gao²,* , Zhonghua Zheng², Binbin Lai¹, Lixia Sheng¹, Zhijuan Xu¹, Xiao Yan¹, Jiaping Wang¹, Shiwei Duan²,* and Guifang Ouyang¹,*

Abstract
Objective: The aim of this prospective randomized controlled clinical trial was to explore the relationship between GPX3 methylation and Pai-Neng-Da (PND) in the treatment of patients with low-risk myelodysplastic syndrome (MDS).

Methods: There were 82 low-risk MDS patients who were randomly divided into the following two groups: androl, thalidomide, and PND capsule (ATP group, n = 41); or androl and thalidomide (AT group, n = 41). Hemoglobin and neutrophil and platelet counts and changes in GPX3 methylation level were assessed.

Results: The plasma hemoglobin level increased in both groups after treatment. However, the platelet count increased only in the ATP group. Patients in the ATP group had a better platelet response than the AT group, and GPX3 methylation markedly decreased after treatment with ATP but not after treatment with AT. Moreover, male patients had a significantly lower GPX3 methylation level than female patients, while platelet counts from male patients increased dramatically after the ATP regimens compared with female patients. GPX3 methylation changes were negatively correlated with platelet changes in ATP group.

¹Department of Hematology, Ningbo First Hospital, Ningbo, Zhejiang, China
²Medical Genetics Center, School of Medicine, Ningbo University, Ningbo, Zhejiang, China

*These authors contributed equally to this work.

Corresponding author:
Guifang Ouyang, Department of Hematology, Ningbo First Hospital, Ningbo, Zhejiang 315010, China.
Email: nbougf@163.com
Conclusion: PND can improve hematological parameters and decrease the GPX3 methylation level. Decreasing GPX3 methylation is associated with the hematologic response that includes platelet in GPX3 methylation.

China Clinical Trial Bureau (ChiCTR; http://www.chictr.org.cn/) registration number: ChiCTR-IOR-15006635.

Keywords
Low-risk myelodysplastic syndrome, GPX3, DNA methylation, Pai-Neng-Da, hematological response, platelet

Date received: 4 February 2020; accepted: 14 August 2020

Introduction
Myelodysplastic syndrome (MDS) is a heterogeneous clonal myeloid disease that is characterized by ineffective hematopoietic function, which is accompanied by abnormal maturation and developmental abnormalities in one or more blood cell lineages.\(^1\) MDS mainly affects elderly patients. The annual incidence of MDS in the elderly population is 12 to 50 per 100,000 people, which is much higher than 3.5 to 10 per 100,000 people for the general population.\(^2,3\) MDS is associated with genetic mutations, immune disorders, chromosomal abnormalities, epigenetic abnormalities, and other factors.\(^4,5\) Therapeutic strategies for low-risk MDS include red blood cell (RBC) infusion and iron chelation therapy, the combined use of hematopoietic growth factors and immunosuppressive agents, and androgen-assisted therapy, but the response to these treatments is unsatisfactory.\(^5-7\)

Numerous studies have shown that glutathione peroxidase is involved in the development and progression of many tumors.\(^8,9\) Glutathione peroxidase 3 (GPX3) is the most widely studied member of the GPX family.\(^10\) GPX3 reduces accumulation of hydrogen peroxide in the body during cellular oxidative metabolism.\(^11,12\) The primary biochemical role of hydrogen peroxide is to modulate the characteristics of cancer cells, including proliferation, invasion, migration, angiogenesis, and apoptosis.\(^13\) Abnormal inactivation or low GPX3 expression may result in the accumulation of excess reactive oxygen species (ROS), including hydrogen peroxide, leading to tumorigenesis.\(^13,14\)

Abnormal DNA methylation at the CpG island of the promoter in tumor-associated genes is a common event in human cancer,\(^14\) which has also been shown to be involved in the development and progression of MDS.\(^14\) It is a biomarker for the prognosis, treatment, and survival of patients with MDS.\(^15-19\) Recently, hypomethylated drugs, such as azacitidine and decitabine, have been shown to have clinical effects in the treatment of MDS.\(^20,21\)

GPX3 hypermethylation is associated with the development and progression of cancer, including gastric cancer, colorectal cancer,\(^21\) chronic myeloid leukemia,\(^22\) and acute promyelocytic leukemia.\(^23\) GPX3 methylation in the bone marrow can also predict poor prognosis of MDS and leukemia transformation.\(^15\) CpG island methylation in the GPX3 gene promoter region has a significant effect on the regulation of GPX3 transcription and expression.\(^24,25\)

The biologically active component in ginseng extract, the panaxadiol saponins component, was isolated from total saponins of ginsenosides using a hematopoiesis
biological activity assay, and it was formulated into capsules that are called Pai-Neng-Da (panaxadiol saponins component, PND), which is a class-five new Chinese patent medicine. The composition and content of PND have been analyzed and defined as five monomers of panaxadiol saponins. The PND patent for treating a variety of pancytopenia has been authorized by the State Intellectual Property Office of China. PND was used subsequently for a series of pharmacodynamics, toxicological, and clinical studies. All research data for the 23 items were submitted to the China Food and Drug Administration (CFDA), and two certificates for the new class-five Chinese patent medicine were authorized and granted by CFDA in 2010, including both PND capsule (approval No. 2010L00856) and panaxadiol saponins component (approval No. 2010L00857). This was then successfully transferred to Ningbo Tianzhen Pharmaceutical Co. Ltd. for clinical trials and commercial production. PND was demonstrated to be safe, and six to ten tablets daily was recommended as a safe dose in a phase I clinical trial. A phase II clinical trial was performed in seven hospitals with a professional advantage for treating primary immune thrombocytopenic purpura (ITP) and chronic angiogenic leukocytopenia (neutropenia). The clinical results confirmed that PND was effective and had no adverse side effects. Consistent with previous studies and as supported by this project, this study used PND+andriol+thalidomide or andriol+thalamidomide to investigate the efficacy of PND in the treatment of low-risk MDS, and to test the association between GPX3 methylation and PND for the adjuvant treatment of patients with MDS.

**Methods**

This study is a subanalysis of a prospective clinical trial that was registered with the China Clinical Trial Bureau (ChiCTR; http://www.chictr.org.cn/; registration number ChiCTR-IOR-15006635).

**Inclusion and exclusion criteria**

Low-risk MDS patients were diagnosed in accordance with the Vienna diagnostic criteria, including refractory anemia (RA), refractory anemia with multilineage dysplasia (RAEB-1), and refractory cytopenia with multilineage dysplasia (RCMD) type. On the basis of the International Prognostic Scoring System (IPSS) score, patients in the low-risk group had a score of 0 to 1.

The following patients are excluded, including pregnant women or women who planned to become pregnant, and breastfeeding women; patients with severe cardiovascular, hepatic, renal system or mental disease; patients with the complication of severe infection; patients with some types of MDS including refractory anemia with increased blasts, 5q-syndrome, MDS that were not classified, or IPSS score ≥1.5 points; or MDS patients who needed more active treatment such as demethylation chemotherapy, chemotherapy, or bone marrow transplantation.

**Drugs**

PND capsule was provided by Ningbo Tianzhen Pharmaceutical Co. Ltd. (Ningbo, China; batch No. 20120101). Specifications were as follows: size 4 gelatin capsules and 40 mg per capsule. Each capsule contained five panaxadiol saponins monomers with a purity of 92.44% as analyzed and defined by high-performance liquid chromatography (HPLC) using specific monomers of ginsenosides as the reference standards. Androl was purchased from Catalent France Beinheim S.A. (Beinheim, France), and thalidomide was purchased from Changzhou Pharmaceutical Factory Co., Ltd. (Changzhou, China).
Study design

Low-risk MDS patients from Ningbo First Hospital (from October 2015 to March 2019) were included in this prospective randomized controlled clinical trial. Patients were randomly divided into two groups. The ATP group comprised patients who received oral androl, thalidomide and PND (PND capsule, ginsengdiol group saponin extract; 40 mg, three capsules at a time twice per day). Andriol Testocaps capsule (80 mg) were taken twice daily, and thalidomide tablets 100 mg were taken before going to bed. Patients in the AT group received oral androl and thalidomide, as follows: Andriol Testocaps capsule 80 mg twice daily; and thalidomide tablets 100 mg before going to bed for a 4-week course of treatment, and there were five courses of medication. The neutrophil count, hemoglobin level, platelet count, hepatic function, and renal function of patients were assessed at the beginning of the experiment and at follow-up. Bone marrow samples from the two groups were collected before and after treatment for 3 months and stored at −80°C until methylation detection. This study was approved by the Human Research Ethics Committees of Ningbo First Hospital (Ethical approval number, 2015-R001, Approval Date, 23 January 2015). All patients provided written informed consent for the bone marrow collection and immunophenotyping research.

Efficacy evaluation

Therapeutic efficacy was evaluated in accordance with the efficacy standard of the MDS International Working Group. In this study, the hematologic improvement including platelet response (HI-P), neutrophil response (HI-N), and erythroid response (HI-E) was our focus, especially HI-P. The major HI-P response was defined as follows: for patients with a pretreatment platelet count that was less than 100,000/mm³, it was defined as an absolute increase of 30,000/mm³ or more; and for platelet transfusion-dependent patients, it was defined as stabilization of the platelet count and platelet transfusion independence. The minor HI-P response was defined as follows: for patients with a pretreatment platelet count less than 100,000/mm³, it was defined as a 50% or more increase in platelet count with a net increase greater than 10,000/mm³ but less than 30,000/mm³. The improvements must last at least 2 months in the absence of ongoing cytotoxic therapy.

DNA methylation detection for GPX3

The Omega DNA Mini Kit (Omega Bio-Tek, Norcross, GA, USA) was used to extract genomic DNA from bone marrow and blood. The bisulfite conversion process of the DNA template was as described in our previous work. The quantitative methylation-specific polymerase chain reaction (PCR) (qMSP) technology, which was based on fluorescent dye (SYBR-Green), was used to quantitatively detect the GPX3 methylation level. The qMSP procedure was performed as follows: 95°C for 10 minutes, then 45 cycles for 30 s at 95°C, 30 s at 58°C, and 30 s at 72°C. Melting curve analysis was performed at 95°C for 15 s and 60°C for 1 minute. The primer sequences for GPX3 were 5′-TGGTTATGTTATGTCGTTCG-3′ (forward primer) and 5′-CCTTACCAACACCCCTTGCAAA-3′ (reverse primer). β-actin was used as an internal reference, and the β-actin sequences were 5′-TGGTGGATGGAGGAGTTGTAAGT-3′ (forward primer) and 5′-AACCCTCAAACCCATCTCCTTAA-3′ (reverse primer). The percentage of methylation reference (PMR) for GPX3 was calculated as previously described.

Statistical analysis

SPSS version 17.0 software (SPSS Inc., Chicago IL, USA) was used for statistical
analysis. Measurement data were presented as the mean ± standard deviation (x ± s). Paired-sample t-tests were used for statistical analysis. Count data were analyzed using the Chi-square test. \( P < 0.05 \) was considered to be statistically different.

**Results**

There were 101 MDS patients included in the main study, and 19 were excluded here because of incomplete data. Thus, 82 MDS patients were included in this subanalysis. There were 26 men and 56 women who were enrolled into this study. Among the enrolled patients, 41 were enrolled into the ATP group and 41 were enrolled into the AT group. The average age of patients in the ATP and AT groups was 53.66 ± 10.86 years and 52.63 ± 13.46 years, respectively. The clinical pathology and biochemical data from patients in the ATP and AT groups were matched for parameters such as age, gender, neutrophils, hemoglobin, and platelets (Table 1).

**ATP promotes hematological improvement in patients with MDS**

After 3 months of treatment, 62.64% (21 of 33) of patients showed a hematologic improvement (platelet response, HI-P) in patients receiving ATP compared with 36.67% (11 of 30) of patients in the AT group. As shown in Figure 1, platelet and hemoglobin increased significantly after 3 months of ATP treatment compared with before treatment (\( n = 41 \); platelets: 73.24 ± 54.54 × 10⁹/L vs. 98.76 ± 75.46 × 10⁹/L, \( P = 0.014 \); hemoglobin: 122.07 ± 24.55 g/L vs. 128.76 ± 26.61 g/L, \( P = 0.012 \)). In addition, platelet and hemoglobin levels were significantly higher in the ATP group after 5 months of treatment compared with before treatment (\( n = 41 \); platelets: 73.24 ± 54.54 × 10⁹/L vs. 103.9 ± 67.53 × 10⁹/L, \( P = 0.001 \); hemoglobin: 122.07 ± 24.55 g/L vs. 134.07 ± 28.48 g/L, \( P < 0.001 \)) (Figure 1a and 1b). However, in the AT group, only hemoglobin showed a significant increase after treatment compared with before treatment (\( n = 41 \); 3 months: 117.29 ± 25.79 g/L vs. 124.64 ± 25.28 g/L, \( P = 0.001 \); or \( n = 41 \), 5 months: 117.29 ± 25.79 g/L vs. 125.85 ± 26.38 g/L, \( P = 0.004 \)) (Figure 1c).

**GPX3 demethylation induced by PND in patients with MDS was related to gender and could promote the recovery of PLT hematopoietic function**

As shown in Figure 2, we selected three CpG sites from the CpG island in the

| Table 1. Basic clinical characteristics of patients. |
|-----------------------------------------------------|
| Variable | Treatment group (n = 41) | Control (n = 41) | p         |
|-----------|--------------------------|-----------------|-----------|
| Sex (n)   |                          |                 |           |
| Male      | 12                       | 14              | N.S.      |
| Female    | 29                       | 27              |           |
| Age (year)| 53.66 ± 10.86            | 52.63 ± 13.46   | N.S.      |
| Baseline before treatment |                   |                 |           |
| Neutrophils (×10⁹/L) | 2.49 ± 2.16          | 2.35 ± 1.41     | N.S.      |
| Hemoglobin (g/L)         | 122.07 ± 24.55        | 117.29 ± 25.79  | N.S.      |
| Platelets (×10⁹/L)       | 73.24 ± 54.54         | 77.37 ± 46.77   | N.S.      |
| Blasts in bone marrow (%)| 0.62 ± 0.813         | 0.73 ± 0.832    | N.S.      |
| Karyotype |                          |                 |           |
| Normal    | 36                       | 37              | N.S.      |
| Abnormal  | 5                        | 4               |           |

N.S., not significant.
GPX3 promoter region to represent GPX3 methylation.30 We examined the bone marrow GPX3 methylation level before and after treatment in 28 ATP-treated patients and 12 AT-treated patients. Our data confirmed that the GPX3 methylation level was significantly reduced in MDS patients after 3 months of ATP treatment compared with before treatment (n = 28; 40.81% ± 32.36% vs. 22.31% ± 16.51%, P = 0.005, Figure 3a). However, there was no difference in GPX3 methylation in patients before or after AT treatment (n = 12; 41.76% ± 31.18% vs. 28.82% ± 20.33%, Figure 3a). In addition, in patients <60 years old, the GPX3 methylation level was significantly reduced after 3 months of ATP treatment compared with before treatment (n = 22; 40.73% ± 34.93% versus 18.68% ± 11.74%, P = 0.009, Figure 3b).
However, GPX3 methylation level was not significantly different in patients receiving AT treatment before and after 3 months of treatment \((n = 11; \text{39.32}\% \pm 31.47\% \text{ vs. } 28.77\% \pm 21.32\%, \text{Figure } 3b)\).

In addition, the GPX3 methylation level and platelet elevation after 3 months of ATP treatment was different when compared by gender. In male patients, the GPX3 methylation level was lower than that of female patients \((n = 8; \text{46.58}\% \pm 31.07\% \text{ vs. } 13.28\% \pm 6.23\%, \text{ } P = 0.035, \text{Figure } 4a)\). Conversely, platelet counts were significantly increased in male patients with lower GPX3 methylation levels compared to females. This difference was more pronounced in male patients with lower GPX3 demethylation compared to female patients (Figure 4a).

**Figure 3.** Comparison of the difference in GPX3 methylation between the ATP and AT groups before and after treatment. a. After 3 months of treatment, GPX3 methylation was significantly reduced in the ATP group compared with before treatment, but there was no difference in the AT group; b. GPX3 methylation in patients who were younger than 60 years in the ATP and AT groups was investigated. GPX3 methylation was significantly lower in the ATP group after compared with before treatment. There was no difference in the AT group after 3 months of treatment compared with before treatment. Before, before 3 months of treatment; After, after 3 months of treatment; ATP, group that received oral androl, thalidomide, and PND capsule; AT, group that received oral androl and thalidomide; PND, Pai-Neng-Da.

**Figure 4.** In patients with low-risk MDS, GPX3 demethylation by ATP may be related to gender, and platelet elevation was more pronounced in male patients with stronger GPX3 demethylation. a. GPX3 demethylation was more pronounced in male MDS patients compared with female MDS patients after 3 months of ATP treatment. b. The platelet count increased significantly in low-risk male compared with low-risk female MDS patients with more significant GPX3 demethylation. Before, before 3 months of treatment; After, after 3 months of treatment; MDS, myelodysplastic syndrome; ATP, group that received oral androl, thalidomide, and PND capsule; PND, Pai-Neng-Da.
compared with female MDS patients (n = 8; 113.58 ± 135.98 vs. 159.5 ± 142.23, P = 0.001, Figure 4b). There was no notable change in the GPX3 methylation level or in the platelet count in female MDS patients who were treated with ATP. Therefore, demethylation of ATP to GPX3 may be associated with overall HI-P in MDS patients.

The demethylation function of PND on GPX3 might be related to the overall HI-P of patients with low-risk MDS

As described above, in the ATP group, GPX3 methylation was significantly reduced in male patients, and platelet counts were significantly increased compared with female patients. To further investigate the relationship between demethylation of GPX3 that is induced by PND and HI-P, we divided bone marrow specimens from the ATP group into a hematologic response group (HI-P, n = 11) and a non-hematologic response group (non-HI-P, n = 11). After 3 months of ATP treatment, platelet counts were significantly increased in HI-P patients compared with before treatment (n = 11; 70.27 ± 31.61 vs. 117.36 ± 34.09, P = 0.003, Figure 5a) while non-HI-P patients showed no change (n = 11). In addition, the GPX3 methylation level was significantly lower in HI-P patients after compared with before ATP treatment (n = 11; 46.63% ± 34.61% vs. 22.58% ± 9.37%, P = 0.047). However, there was no significant change in GPX3 methylation in the non-HI-P group after compared with before ATP treatment (n = 11; 40.9% ± 35.91% vs. 36.44% ± 52.47%, Figure 5b). Moreover, GPX3 methylation was inversely correlated with changes in platelet count in patients with low-risk MDS (r = −0.352, P = 0.048, Figure 6). Our results suggest that PND increases the platelet count and promotes hematopoiesis by decreasing the GPX3 methylation level.

Discussion

A series of preclinical studies of PND31–33 were preformed including pharmacodynamic studies in animal models with hemocytopenia, cell biology, molecular biology experiments, and toxicological studies to test the biologically active panaxadiol saponins component. These studies demonstrated

Figure 5. Effect of the change in GPX3 methylation on the hematological response to low-risk MDS patients with ATP treatment. A. Compared with the Non HI-P group, platelet counts of patients in the HI-P group increased significantly after treatment. B. GPX3 methylation decreased significantly in patients with a hematological improvement (HI-P), and those without hematological improvement (Non HI-P) had the negative results after treatment compared with before treatment.

Before, before 3 months of treatment; After, after 3 months of treatment; MDS, myelodysplastic syndrome; ATP, ATP group that received oral androl, thalidomide, and PND capsule; PND, Pai-Neng-Dal HI-P; hematological improvement in platelet response.
that PND possessed dual activity, i.e., promoting proliferation and differentiation of hematopoietic progenitor cells and regulating the immune function. PND reduced peripheral blood CD8+ cells, and increased CD4+ cells, returning the CD4+-to-CD8+ cell ratio to normal. It reduced the myelosuppression of bone marrow that was caused by chemotherapy, accelerated bone marrow recovery, and increased the peripheral WBC and platelet count, as shown by mice treated with hemocytopenia that was caused by cyclophosphamide chemotherapy. PND was effective in promoting proliferation for the three lineages of hematopoietic progenitor cells, increasing erythroid, myeloid, and megakaryocytic progenitor cell colony formation in bone marrow culture. A pharmacodynamic study in CD34+ hematopoietic stem/progenitor cells suggested that PND was effective in promoting hematopoiesis and inducing differentiation, which suggests that its activity is similar to that of hematopoietic growth factors. PND promotes hematopoiesis using an intracellular signal pathway, and it induced the up-regulation of multiple transcription factors such as GATA-1, GATA-2, c-Fos, c-Jun, and NF-E2, and their protein expression level, phosphorylation status, and DNA binding activities were increased dramatically by PND treatment in hematopoietic cells, thereby promoting hematopoiesis and blood cell formation. However, in this study, PND improved hematopoietic function in low-risk MDS patients by promoting GPX3 demethylation.

In this study, after 3 months of treatment with ATP, the platelet count was significantly elevated in patients with low-risk MDS, and patients achieving HI-P. However, the GPX3 methylation level was significantly reduced in the ATP group patients and in HI-P patients, and the GPX3 methylation level was significantly lower in male patients in the ATP group after compared with before treatment. The platelet counts were also significantly increased in male compared with female patients. These findings suggest that GPX3 demethylation of PND may be associated with improving the hematopoietic function. In patients with low-risk MDS, there may be an inverse correlation between platelet hematology improvement and GPX3 methylation levels.

Figure 6. Correlation between the changes in GPX3 methylation and PLT counts before and after ATP treatment.

PLT, platelet; ATP, ATP group that received oral androl, thalidomide, and PND capsule; PND, Pai-Neng-Da.
In our study, the hemoglobin level was significantly increased in both groups. After 3 months of treatment, 62.64% of ATP patients and 36.67% of AT patients achieved HI-P, indicating that PND as an auxiliary drug provided a better clinical outcome in low-risk MDS. Thrombocytopenia is common in patients with MDS and the estimated prevalence is 40% to 65%. The average platelet component mean platelet volume is a useful screening marker for MDS. MDS patients with thrombocytopenia have a poor prognosis. Bleeding complications are a major cause of morbidity and mortality, and thrombocytopenia is also an independent factor in reducing survival. This has been included in the updated prognostic scoring system. Platelet transfusion is a necessary support for clinically significant thrombocytopenia. MDS patients with severe thrombocytopenia may benefit from the recovery of platelet activity and further allo-hematopoietic stem cell transplantation (HSCT) after decitabine treatment.

In this study, the platelet count was significantly increased after 3 months of treatment in the ATP group compared with before treatment, indicating that PND capsule has a positive effect on enhancing hematopoietic function and improving symptoms in low-risk MDS patients.

Promoter DNA hypermethylation and down-regulation of the \( GPX3 \) gene occur in a variety of solid tumors. The \( GPX3 \) promoter is methylated in chronic myelogenous leukemia, and \( GPX3 \) hypermethylation is an independent prognostic biomarker in non-M3 acute myeloid leukemia. The preliminary study also reported that \( GPX3 \) methylation in the bone marrow was associated with poor prognosis of MDS and leukemia transformation. \( GPX3 \) may be a predictor of NKTL and NESM response chemotherapy. Additionally, \( GPX3 \) hypermethylation in gastric cancer (GC) predicted a shorter tumor recurrence time in patients aged >60 years. In the current study, we observed a significant decrease in \( GPX3 \) methylation levels in MDS patients after a 3-month ATP regimen compared with before treatment. Similarly, the methylation level of patients in the ATP group was significantly lower in patients under, compared with over, 60 years of age. We also found a significant decrease in the \( GPX3 \) methylation level in MDS patients who received HI-P after a 3-month ATP regimen compared with before treatment, but we found no significant difference of \( GPX3 \) methylation in the non-HI-P MDS patients before or after treatment. Additionally, after a 3-month ATP regimen, the \( GPX3 \) methylation level in male patients was lower than that of female patients. HI-P or an increase in the platelet count in male MDS patients was more pronounced than that in female MDS patients. Because of the increased ROS production that was associated with platelet activation and apoptosis, \( GPX3 \) can reduce platelet apoptosis while enhancing their activity as a ROS scavenger to increase the platelet count. However, a few results of the statistical analysis were not meaningful owing to the moderate sample size. We have reason to hypothesize that \( GPX3 \) expression in low-risk MDS patients is regulated by epigenetic regulation of DNA methylation and that PND may reduce the \( GPX3 \) methylation level, leading to up-regulation of \( GPX3 \) expression, which thereby increases the platelet count and improves hematopoietic function.

In this study, we enrolled 82 patients who had low-risk MDS, which did not reach the expected number of cases, and this may affect the statistical significance of the results. However, in conclusion, the study shows, to a certain extent, that PND capsule is able to increase the platelet count to obtain HI-P in low-risk MDS patients, which showed better results than the group.
without PND. Decreasing the GPX3 methylation level may be involved in the hematological improvement process, and the effect of PND on the GPX3 methylation level provides clues to the drug action mechanism of PND capsules.

Declaration of conflicting interest
The authors declare that there is no conflict of interest.

Funding
This research was supported by the traditional Chinese medicine administration of Zhejiang Province (Grant No. 2015ZZ018), the National Science Foundation of Zhejiang Province (Grant No. LY17H160005), the Zhejiang Medical and Health Science and Technology Project (Grant No. 2019KY158), the National Science Foundation of Ningbo (Grant No. 2018A610390), and grants from K. C. Wong Magna Fund at Ningbo University.

ORCID iD
Guifang Ouyang https://orcid.org/0000-0002-3411-3666

References
1. Gao RL and Chong BH. Research and development of the effective components of panaxdiol saponin as new Chinese patent medicine for treating hemocytopenia. Chin J Integr Med 2012; 18: 897–902.
2. Babushok DV and Bessler M. Genetic predisposition syndromes: when should they be considered in the work-up of MDS? Best Pract Res Clin Haematol 2015; 28: 55–68.
3. Nishino HT and Chang CC. Myelodysplastic syndromes: clinicopathologic features, pathobiology, and molecular pathogenesis. Arch Pathol Lab Med 2005; 129: 1299–1310.
4. Kennedy JA and Ebert BL. Clinical implications of genetic mutations in myelodysplastic syndrome. J Clin Oncol 2017; 35: 968–974.
5. Boddu P, Kantarjian H, Garcia-Manero G, et al. The emerging role of immune checkpoint based approaches in AML and MDS. Leuk Lymphoma 2018; 59: 790–802.
6. Ortega J, Komrokji R and List AF. The hematopoietic growth factors in the myelodysplastic syndromes. Cancer Treat Res 2011; 157: 363–382.
7. Smith AR, Warlick ED, Roesler MA, et al. Factors associated with hematopoietic cell transplantation (HCT) among patients in a population-based study of myelodysplastic syndrome (MDS) in Minnesota. Ann Hematol 2015; 94: 1667–1675.
8. Doroshow JH and Juhasz A. Modulation of selenium-dependent glutathione peroxidase activity enhances doxorubicin-induced apoptosis, tumor cell killing, and hydroxyl radical production in human NCI/ADR-RES cancer cells despite high-level P-glycoprotein expression. Free Radic Res 2019; 53: 882–891.
9. Habyarimana T, Bakri Y, Mugenzi P, et al. Association between glutathione peroxidase 1 codon 198 variant and the occurrence of breast cancer in Rwanda. Mol Genet Genomic Med 2018; 6: 268–275.
10. Brigelius-Flohe R and Maiorino M. Glutathione peroxidases. Biochim Biophys Acta 2013; 1830: 3289–3303.
11. Tham DM, Whitin JC, Kim KK, et al. Expression of extracellular glutathione peroxidase in human and mouse gastrointestinal tract. Am J Physiol 1998; 275: G1463–G1471.
12. Yamamoto Y and Takahashi K. Glutathione peroxidase isolated from plasma reduces phospholipid hydroperoxides. Arch Biochem Biophys 1993; 305: 541–545.
13. Brigelius-Flohe R and Kipp A. Glutathione peroxidases in different stages of carcinogenesis. Biochim Biophys Acta 2009; 1790: 1555–1568.
14. Waris G and Ahsan H. Reactive oxygen species: role in the development of cancer and various chronic conditions. J Carcinog 2006; 5: 14.
15. Zhou JD, Lin J, Zhang TJ, et al. GPX3 methylation in bone marrow predicts adverse prognosis and leukemia transformation in myelodysplastic syndrome. Cancer Med 2017; 6: 267–274.
16. Khan H, Vale C, Bhagat T, et al. Role of DNA methylation in the pathogenesis and
treatment of myelodysplastic syndromes. Semin Hematol 2013; 50: 16–37.
17. Zhao X, Yang F, Li S, et al. CpG island methylator phenotype of myelodysplastic syndrome identified through genome-wide profiling of DNA methylation and gene expression. Br J Haematol 2014; 165: 649–658.
18. Lo-Coco F, Fouad TM and Ramadan SM. Acute leukemia in women. Womens Health (Lond) 2010; 6: 239–249.
19. Lybeert ML, De Neve W, Vrints LW, et al. Primary gastric non-Hodgkin's lymphoma stage IE and IIE. Eur J Cancer 1996; 32A: 2306–2311.
20. Kantarjian H, Issa JP, Rosenfeld CS, et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 2006; 106: 1794–1803.
21. Kantarjian H, Oki Y, Garcia-Manero G, et al. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 2007; 109: 52–57.
22. Yao DM, Zhou JD, Zhang YY, et al. GPX3 promoter is methylated in chronic myeloid leukemia. Int J Clin Exp Pathol 2015; 8: 6450–6457.
23. GPX3 hypermethylation serves as an independent prognostic biomarker in non-M3 acute myeloid leukemia [Retraction]. Am J Cancer Res 2016; 6: 2389.
24. He Y, Wang Y, Li P, et al. Identification of GPX3 epigenetically silenced by CpG methylation in human esophageal squamous cell carcinoma. Dig Dis Sci 2011; 56: 681–688.
25. Jee CD, Kim MA, Jung EJ, et al. Identification of genes epigenetically silenced by CpG methylation in human gastric carcinoma. Eur J Cancer 2009; 45: 1282–1293.
26. Shao KD, Zhou YH, Shen YP, et al. Treatment of 37 patients with refractory idiopathic thrombocytopenic purpura by shengxueling. Chin J Integr Med 2007; 13: 33–36.
27. Kuang YM, Zhu Y, Gao RL, et al. Clinical study of pai-neng-da capsule in the treatment of chronic aplastic anemia. Chin J Integr Med 2016; 22: 124–129.
28. Cheson BD, Bennett JM, Kantarjian H, et al. Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood 2000; 96: 3671–3674.
29. Ying X, Chen Y, Zheng Z, et al. Gout in males: a possible role for COMT hypomethylation. Clin Rheumatol 2019; 38: 2865–2871.
30. Zhou C, Pan R, Li B, et al. GPX3 hypermethylation in gastric cancer and its prognostic value in patients aged over 60. Future Oncol 2019; 15: 1279–1289.
31. Gao RL, Xu CL, Jin JM. Effect of total saponins of Panax ginseng on hematopoietic progenitor [Chinese]. Zhongguo Zhong Xi Yi Jie He Za Zhi. 1992; 12: 285–262.
32. Gai Y, Gao RL, Niu YP. Effect of Panax notoginsenosides on the proliferation of hematopoietic progenitor cells in mice with immune-mediated aplastic anemia [Chinese]. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2003; 23: 680–683.
33. Qian XD, Gao RL, Ma K, et al. Proliferation and differentiation of human CD34+ hematopoietic stem/progenitor cells induced by Panax notoginsenosides. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2003; 11: 120–123.
34. Jin J, Tao H, Gao R. Effect of ginsenosides on proliferation and differentiation of human CD34+ hematopoietic stem/progenitor cells [Chinese]. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2000; 20: 673–676.
35. Lu FR, Shen L, Qin Y, et al. Clinical observation on trigonella foenum-graecum L. total saponins in combination with sulfonylureas in the treatment of type 2 diabetes mellitus. Chin J Integr Med 2008; 14: 56–60.
36. Gao RL. Research and development of new Chinese materia medica for treatment of refractory hematopathy by establishment and application of multiple technique platforms. Chin J Integr Med 2007; 13: 95–97.
37. Fang GL, Gao RL, Lin XJ, et al. [Effects of Ginseng panaxadiol saponin on proliferation and differentiation of human bone marrow CD34+ cells]. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2007; 15: 776–779.
38. Sun X, Zhao YN, Qian S, et al. Ginseng-derived panaxadiol saponins promote
hematopoiesis recovery in cyclophosphamide-induced myelosuppressive mice: potential novel treatment of chemotherapy-induced cytopenias. *Chin J Integr Med* 2018; 24: 200–206.

39. Masutani R, Ikemoto T, Maki A, et al. Mean platelet component and mean platelet volume as useful screening markers for myelodysplastic syndrome. *Health Sci Rep* 2018; 1: e50.

40. Waisbren J, Dinner S, Altman J, et al. Disease characteristics and prognosis of myelodysplastic syndrome presenting with isolated thrombocytopenia. *Int J Hematol* 2017; 105: 44–51.

41. Miyazaki Y. [Revised international prognostic scoring system (IPSS-R) for myelodysplastic syndromes]. *Rinsho Ketsueki* 2013; 54: 545–551.

42. Li W, Morrone K, Kambhampati S, et al. Thrombocytopenia in MDS: epidemiology, mechanisms, clinical consequences and novel therapeutic strategies. *Leukemia* 2016; 30: 536–544.

43. Feng Q, Hu DY, Yang JG, et al. [Effects of socioeconomic status on the distribution of cardiovascular risk factors and clinical treatments of patients with acute myocardial infarction in Beijing]. *Zhonghua Liu Xing Bing Xue Za Zhi* 2008; 29: 430–433.

44. Tang Y, Zhang X, Han S, et al. Prognostic significance of platelet recovery in myelodysplastic syndromes with severe thrombocytopenia. *Clin Appl Thromb Hemost* 2018; 24: 217S–222S.

45. Zhu X, Wang J, Li L, et al. GPX3 suppresses tumor migration and invasion via the FAK/AKT pathway in esophageal squamous cell carcinoma. *Am J Transl Res* 2018; 10: 1908–1920.

46. An BC, Choi YD, Oh IJ, et al. GPx3-mediated redox signaling arrests the cell cycle and acts as a tumor suppressor in lung cancer cell lines. *PLoS One* 2018; 13: e0204170.

47. Zhou C, Hu H, Zheng Z, et al. Association between GPX3 promoter methylation and malignant tumors: a meta-analysis. *Pathol Res Pract* 2019; 215: 152443.

48. Gong Y, Pu W, Jin H, et al. Quantitative proteomics of CSF reveals potential predicted biomarkers for extranodal NK-/T-cell lymphoma of nasal-type with ethmoidal sinus metastasis. *Life Sci* 2018; 198: 94–98.

49. Hosseini E, Ghasemzadeh M, Atashibarg M, et al. ROS scavenger, N-acetyl-l-cysteine and NOX specific inhibitor, VAS2870 reduce platelets apoptosis while enhancing their viability during storage. *Transfusion* 2019; 59: 1333–1343.